{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:08:39Z","timestamp":1784740119370,"version":"3.55.0"},"reference-count":36,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1684\/ejd.2018.3444","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:21:02Z","timestamp":1696864862000},"page":"764-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory S\u00e9zary syndrome: a systematic review"],"prefix":"10.1684","volume":"28","author":[{"given":"Jacob R.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather W.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"3444_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2013.07.049","volume":"70","author":"SI Jawed","year":"2014","unstructured":"Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014; 70: 205.e1\u201316, quiz 21\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"3444_CR2","first-page":"529","volume":"2015","author":"M Duvic","year":"2015","unstructured":"Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and S\u00e9zary syndrome. ASH Educ Program Book 2015; 2015: 529\u201344.","journal-title":"ASH Educ Program Book"},{"key":"3444_CR3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/j.1365-2141.2008.07557.x","volume":"144","author":"JG Gribben","year":"2009","unstructured":"Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144: 818\u201331.","journal-title":"Br J Haematol"},{"key":"3444_CR4","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"3444_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015; 8: 2\u201310.","journal-title":"J Evid Based Med"},{"key":"3444_CR6","volume-title":"Development of a quality appraisal tool for case series studies using a modified Delphi technique","author":"C Moga","year":"2012","unstructured":"Moga C, Guo B, Schopflocher D, Harstall C. Development of a quality appraisal tool for case series studies using a modified Delphi technique. 2012. Available at: http:\/\/www.ihe.ca\/publications\/development-of-a-quality-appraisal-tool-for-case-series-studies-using-a-modified-delphi-technique (accessed 25 July, 2017)."},{"key":"3444_CR7","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S\u00e9zarysyndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 2598\u2013607.","journal-title":"J Clin Oncol"},{"key":"3444_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am Clin Oncol 1982; 5: 649\u201356.","journal-title":"Am Clin Oncol"},{"key":"3444_CR9","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol 1999; 17: 1244.","journal-title":"J Clin Oncol"},{"key":"3444_CR10","unstructured":"P values were calculated using GraphPad QuickCalcs. Available at: https:\/\/www.graphpad.com\/quickcalcs\/contingency1\/(accessed 30 October, 2017)."},{"key":"3444_CR11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.leukres.2007.11.009","volume":"32","author":"L Alinari","year":"2008","unstructured":"Alinari L, Geskin L, Grady T, et al. Subcutaneous alemtuzumab for S\u00e9zary syndrome in the very elderly. Leuk Res 2008; 32: 1299\u2013303.","journal-title":"Leuk Res"},{"key":"3444_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.11127","volume":"92","author":"MG Bernengo","year":"2007","unstructured":"Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784\u201394.","journal-title":"Haematologica"},{"key":"3444_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1385\/MO:20:4:389","volume":"20","author":"S Capalbo","year":"2003","unstructured":"Capalbo S, Delia M, Dargenio M, et al. Mycosis fun-goides\/S\u00e9zary syndrome. Med Oncol 2003; 20: 389\u201396.","journal-title":"Med Oncol"},{"key":"3444_CR14","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.1111\/bjd.12690","volume":"170","author":"A de Masson","year":"2014","unstructured":"de Masson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 2014; 170: 7204.","journal-title":"Br J Dermatol"},{"key":"3444_CR15","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.ad.2015.02.008","volume":"106","author":"E del Alcazar-Viladomiu","year":"2015","unstructured":"del Alcazar-Viladomiu E, Tuneu-Valls A, Lopez-Pestana A, Vidal-Mancenido MJ. Treatment of Sezary syndrome with alemtuzumab: a series of 5 cases and a review of the literature. Actas Dermosifiliogr 2015; 106: e33\u20139.","journal-title":"Actas Dermosifiliogr"},{"key":"3444_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.0902-4441.2004.00169.x","volume":"72","author":"O Gautschi","year":"2004","unstructured":"Gautschi O, Blumenthal N, Streit M, et al. Successful treatment of chemotherapy-refractory Sezary syndrome with alemtuzumab (Campath-1H). Eur J Haematol 2004; 72: 61\u20133.","journal-title":"Eur J Haematol"},{"key":"3444_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","volume":"71","author":"GA Kennedy","year":"2003","unstructured":"Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003; 71: 250\u20136.","journal-title":"Eur J Haematol"},{"key":"3444_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","volume":"104","author":"DJ Lenihan","year":"2004","unstructured":"Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/S\u00e9zary syndrome. Blood 2004; 104:655.","journal-title":"Blood"},{"key":"3444_CR19","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R, et al. Phase 2 studyofalemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome. Blood 2003; 101:4267\u201372.","journal-title":"Blood"},{"key":"3444_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/09546634.2015.1086479","volume":"27","author":"S Novelli","year":"2016","unstructured":"Novelli S, Garcia-Muret P, Sierra J, Briones J. Alemtuzumab treatment for Sezary syndrome: a single-center experience. J Dermatolog Treat 2016; 27: 179\u201381.","journal-title":"J Dermatolog Treat"},{"key":"3444_CR21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5070\/D37F79243D","volume":"17","author":"A Oliveira","year":"2011","unstructured":"Oliveira A, Lobo I, Alves R, et al. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab. Dermatol Online J 2011; 17:6.","journal-title":"Dermatol Online J"},{"key":"3444_CR22","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3109\/10428190903216770","volume":"50","author":"C Querfeld","year":"2009","unstructured":"Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009; 50: 1969\u201376.","journal-title":"Leuk Lymphoma"},{"key":"3444_CR23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1590\/abd1806-4841.20164322","volume":"91","author":"CMA Reifs","year":"2016","unstructured":"Reifs CMA, Salido-Vallejo R, Garnacho-Saucedo GM, et al. Alemtuzumab in refractory S\u00e9zary syndrome. An Bras Dermatol 2016; 91: 642\u20134.","journal-title":"An Bras Dermatol"},{"key":"3444_CR24","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","volume":"119","author":"SM Horwitz","year":"2012","unstructured":"Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012; 119: 4115.","journal-title":"Blood"},{"key":"3444_CR25","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood.V126.23.5068.5068","volume":"126","author":"JR Lopez","year":"2015","unstructured":"Lopez JR. Mexican patient with refractory mycosis fungoides successfully treated with pralatrexate at low doses: case report. Blood 2015; 126: 5068.","journal-title":"Blood"},{"key":"3444_CR26","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.3816\/CLM.2009.n.079","volume":"9","author":"T Buhl","year":"2009","unstructured":"Buhl T, Bertsch HP, Kaune KM, et al. Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides. Clin Lymphoma Myeloma 2009; 9: E21\u20134.","journal-title":"Clin Lymphoma Myeloma"},{"key":"3444_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","volume":"7","author":"M Duvic","year":"2006","unstructured":"Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006; 7: 51\u20138.","journal-title":"Clin Lymphoma Myeloma"},{"key":"3444_CR28","first-page":"479","volume":"12","author":"MC Fargnoli","year":"2002","unstructured":"Fargnoli MC, Peris K, Francesconi F, et al. Granulomatous mycosis fungoides responsive to gemcitabine. Eur J Dermatol 2002; 12: 479\u201381.","journal-title":"Eur J Dermatol"},{"key":"3444_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1365-2133.2009.09230.x","volume":"161","author":"K Jidar","year":"2009","unstructured":"Jidar K, Ingen-Housz-Oro S, Beylot-Barry M, et al. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. Br J Dermatol 2009; 161: 660\u20133.","journal-title":"Br J Dermatol"},{"key":"3444_CR30","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/cncr.21449","volume":"104","author":"E Marchi","year":"2005","unstructured":"Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Cancer 2005; 104: 2437\u201341.","journal-title":"Cancer"},{"key":"3444_CR31","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00277-014-2121-1","volume":"93","author":"C Pellegrini","year":"2014","unstructured":"Pellegrini C, Stefoni V, Casadei B, et al. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Ann Hematol 2014;93: 1853\u20137.","journal-title":"Ann Hematol"},{"key":"3444_CR32","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","volume":"18","author":"PL Zinzani","year":"2000","unstructured":"Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18: 2603\u20136.","journal-title":"J Clin Oncol"},{"key":"3444_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CFM Hughes","year":"2015","unstructured":"Hughes CFM, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy. Blood 2015; 125:71.","journal-title":"Blood"},{"key":"3444_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1365-2141.2011.08620.x","volume":"154","author":"AB Alexandroff","year":"2011","unstructured":"Alexandroff AB, Shpadaruk V, Bamford WM, Kennedy DBJ, Burd R, Dyer MJS. Alemtuzumab-resistant S\u00e9zary syndrome responding to zanolimumab. Br J Haematol 2011; 154: 419\u201321.","journal-title":"Br J Haematol"},{"key":"3444_CR35","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1182\/blood-2004-11-4314","volume":"105","author":"J Lundin","year":"2005","unstructured":"Lundin J, Kennedy B, Dearden C, Dyer MJS, \u00d6sterborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fun-goides\/S\u00e9zary syndrome. Blood 2005; 105: 4148.","journal-title":"Blood"},{"key":"3444_CR36","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","volume":"42","author":"F Trautinger","year":"2006","unstructured":"Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome. Eur J Cancer 2006; 42: 1014\u201330.","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2018.3444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2018.3444\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2018.3444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2018.3444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:23:29Z","timestamp":1741191809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2018.3444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3444"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2018.3444","relation":{},"ISSN":["1952-4013"],"issn-type":[{"value":"1952-4013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2 Mai 2018","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 Mai 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}